Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma (NCT05070403)

🧪 Interventions in This Study

• Afatinib 40 MG (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• Moffitt Cancer Center — Tampa, Florida

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Squamous Cell Carcinoma

• Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). — Houston, Texas
• Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1. — Victor, New York
• 1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck — Baltimore, Maryland
• Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment — Hamilton, Ontario
• Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) — Pittsburgh, Pennsylvania

Explore by condition: All Squamous Cell Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.